WASHINGTON – A drug already used to fight ovarian and lung cancers received expanded federal approval Thursday as part of a combined treatment for late-stage cervical cancer.
The combination of the drug, Hycamtin, and cisplatin is the first drug treatment for women for whom surgery or radiation therapy is unlikely to be effective against cervical cancer that's incurable, recurrent or persistent and has spread to other organs, the Food and Drug Administration said.
The FDA originally approved Hycamtin in 1996 for treating ovarian cancer and in 1998 for small-cell lung cancer. GlaxoSmithKline makes Hycamtin, also called topotecan hydrochloride.
The drug treatment is not a cure, but can provide a life-prolonging option for women. In clinical trials involving 293 women, patients who received Hycamtin and cisplatin survived a little more than nine months, about three months longer than those on cisplatin alone.
Hycamtin works by damaging the genetic material contained in cancer cells and killing them as they divide.
Patients on the drug face a significant risk of a drop in their white blood counts, which can leave them vulnerable to infection. Other side effects include a decrease in blood platelets, which can lead to excessive bleeding and anemia.
Earlier this month, a Merck & Co. Inc. vaccine to protect against the two strains of the human papillomavirus responsible for most cases of cervical cancer received FDA approval. GlaxoSmithKline also is developing a human papillomavirus vaccine.
Each year, there are about 10,000 new cases of cervical cancer diagnosed in U.S. women and 3,700 deaths.